Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Frishman

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
American Heart Journal|May 1, 1980
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 13. The beta-adrenoceptor blocking drugs: a perspectiveW Frishman
American Heart Journal|January 1, 1980
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 9. Nadolol: a new long-acting beta-adrenoceptor blocking drugW Frishman
American Heart Journal|May 1, 1979
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic propertiesW Frishman
American Heart Journal|June 1, 1979
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effectsW Frishman, R Silverman
American Heart Journal|July 1, 1979
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applicationsW Frishman, R Silverman
American Heart Journal|November 1, 1979
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalolW Frishman, S Halprin
Lung|January 1, 1980
Primary pulmonary hypertension: modern approaches to an old problemS Fein, W Frishman
American Journal of Hypertension|March 21, 1998
Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patientsM Moser, W Frishman
American Heart Journal|September 1, 1980
Cardiovascular effects of phenothiazinesU Elkayam, W Frishman
Archivos Del Instituto De Cardiologia De Mexico|March 1, 1977
[Use of aspirin in ischemic heart disease]W Frishman, S Horwitz
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
American Heart Journal|May 1, 1980
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 13. The beta-adrenoceptor blocking drugs: a perspectiveW Frishman
American Heart Journal|January 1, 1980
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 9. Nadolol: a new long-acting beta-adrenoceptor blocking drugW Frishman
American Heart Journal|May 1, 1979
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic propertiesW Frishman
American Heart Journal|June 1, 1979
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effectsW Frishman, R Silverman
American Heart Journal|July 1, 1979
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applicationsW Frishman, R Silverman
American Heart Journal|November 1, 1979
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalolW Frishman, S Halprin
Lung|January 1, 1980
Primary pulmonary hypertension: modern approaches to an old problemS Fein, W Frishman
American Journal of Hypertension|March 21, 1998
Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patientsM Moser, W Frishman
American Heart Journal|September 1, 1980
Cardiovascular effects of phenothiazinesU Elkayam, W Frishman
Archivos Del Instituto De Cardiologia De Mexico|March 1, 1977
[Use of aspirin in ischemic heart disease]W Frishman, S Horwitz
Pageof 8